Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed Showcases Neflamapimod Benefits for Lewy Body Dementia
    CervoMed Showcases Neflamapimod Benefits for Lewy Body Dementia

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151536/0/en/CervoMed-Highlights-Neflamapimod-s-Potential-Benefits-in-Session-on-Dementia-with-Lewy-Bodies-at-the-150th-Annual-American-Neurology-Association-Conference.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    CervoMed: RewinD-LB Trial Shows Neflamapimod Slows Dementia
    CervoMed: RewinD-LB Trial Shows Neflamapimod Slows Dementia

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122322/0/en/CervoMed-Announces-32-Week-Data-from-RewinD-LB-Trial-Extension-Phase-Showing-Neflamapimod-s-Sustained-Effect-on-Slowing-Clinical-Progression-in-Patients-with-Dementia-with-Lewy-Bod.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    CervoMed Announces Presentations at Alzheimer’s Congress 2025
    CervoMed Announces Presentations at Alzheimer’s Congress 2025

    08 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/08/3111598/0/en/CervoMed-Announces-Late-Breaking-Presentations-at-Alzheimer-s-Association-International-Congress-2025.html

    GLOBENEWSWIRE
    08 Jul 2025
    Share Share
    CervoMed Hires to Support Neflamapimod Development
    CervoMed Hires to Support Neflamapimod Development

    10 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/10/3096571/0/en/CervoMed-Announces-New-Hire-to-Support-Neflamapimod-Development-and-Commercialization.html

    GLOBENEWSWIRE
    10 Jun 2025
    Share Share
    Neflamapimod Slow Dementia Progression in Lewy Bodies at AD/PD 2025
    Neflamapimod Slow Dementia Progression in Lewy Bodies at AD/PD 2025

    02 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/02/3054108/0/en/Investigators-to-Present-Clinical-Trial-Results-Showing-Neflamapimod-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies-in-Oral-Presentation-at-AD-PD-2025.html

    GLOBENEWSWIRE
    02 Apr 2025
    Share Share
    CervoMed Reports 2024 Financial Results and Corporate Updates
    CervoMed Reports 2024 Financial Results and Corporate Updates

    17 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/17/3043647/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    17 Mar 2025
    Share Share